Palisade Capital Management’s Amgen AMGN Stock Holding History

Palisade Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,780	Closed	-$456K	–	434
2017 Q1	$456K	Buy	+2,780	New	+$462K	0.02%	380

Other funds holding AMGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Palisade Capital Management's AMGN Position: Q2 2017 in Review

Palisade Capital Management sold out of Amgen (AMGN) in Q2 2017, closing a stake of 2,780 shares — an estimated $456K sold.

Palisade Capital Management first reported a position in AMGN in Q1 2017 and held it in 1 quarter. The position peaked at $456K in Q1 2017. 1,595 funds tracked by Wall St. Rank hold AMGN as of Q2 2017.

Palisade Capital Management reported no remaining Amgen position as of Q2 2017 after selling out during the quarter.
Palisade Capital Management sold 2,780 Amgen shares in Q2 2017, an estimated $456K.
Palisade Capital Management first reported a position in Amgen in Q1 2017 and held it in 1 quarter.
Palisade Capital Management's Amgen position peaked at $456K in Q1 2017.
1,595 funds tracked by Wall St. Rank held Amgen as of Q2 2017.

Based on Palisade Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.